Beta2-microglobulin-selective adsorbent column (Lixelle) for the treatment of dialysis-related amyloidosis.
Lixelle is a direct hemoperfusion-type adsorbent column developed for selective elimination of beta2-microglobulin (beta2-m) from the circulating blood of patients with dialysis-related amyloidosis (DRA). Lixelle S-35, that has a column volume of 350 mL, efficiently eliminates beta2-m and improves symptoms of DRA such as joint pain and nocturnal awakening. The performance of Lixelle S-15, that has a column volume of 150 mL, is dependent on the dialysis membrane used in combination with the adsorbent column in a hemodialysis circuit. The combination of S-15 and a dialysis membrane with a high beta2-m clearance eliminates an amount of beta2-m that is nearly equal to the amount removed by using S-35. Treatment with S-15 for 6 months improved joint pain with an efficacy similar to that observed when using S-35. The major adverse effects were hypotension and decrease in hematocrit, and these incidences were much less in S-15 compared to S-35.
Suzuki
Kazuo
K
Medical Devices Division, Kaneka Corporation, Osaka, Japan. kazuo.suzuki@kn.kaneka.co.jp
Shimazaki
Masami
M
Kutsuki
Hidetoshi
H
D000327:Adsorption; D000686:Amyloidosis / Q000209:etiology / Q000628:therapy*; D001672:Biocompatible Materials; D002986:Clinical Trials as Topic; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D008567:Membranes, Artificial; D006435:Renal Dialysis / Q000009:adverse effects* / Q000379:methods; D012680:Sensitivity and Specificity; D001613:beta 2-Microglobulin / Q000737:chemistry*
D001672:Biocompatible Materials; D008567:Membranes, Artificial; D001613:beta 2-Microglobulin